

Kadian Value Proposition

Medical Affairs 24 July 2012




CONFIDENTIAL - SUBJECT TO PROTECTIVE ORDER




BARRETT_MDL_00000850

Agenda

Disease Overview/Treatment Guidelines
Clinical Program
MOA/unique formulation
PK/PD
Efficacy/Safety
LT Efficacy/Safety
Dosing flexibility





CONFIDENTIAL - SUBJECT TO PROTECTIVE ORDER

Transition of Acute Postoperative Pain to Persistent Pair

Unresolved Acute¹

- Reported by approximately 50% of patients
- Associated with significant physiological, emotional, mental, and economic consequences

Chronic Postsurgical²

- Reported by about 30% of patients after specific types of major surgery
- RCTs needed to determine which anesthetic interventions reduce risk


The etiology and treatment of pain produced by surgery is different than clinical pain conditions such as rheumatoid arthritis³

Abbreviation: RCT = randomized controlled trial

Source: 1. Polomano RC, et al. J Perianesth Nurs. 2008;23(1 Suppl):S4-S14.; 2. De Kock M. Anesthesiology. 2009;111(3):461-463.; 3. Brennan TJ. Pain. 2011;152(3 Suppl):S33-S40.

CONFIDENTIAL - SUBJECT TO PROTECTIVE ORDER

BARRETT MDL 00000854



CONFIDENTIAL - SUBJECT TO PROTECTIVE ORDER

Need to replace or recreate graphic if slide used (or use reference's original illustration) AH: I called medscape, got transferred 4 times and then left a vm for someone regarding graphics...


CONFIDENTIAL - SUBJECT TO PROTECTIVE ORDER

BARRETT_MDL_00000856


National Dispensed Prescription Data: SDI, Vector One®: National (VONA)

- SDI's Vector One®: National (VONA) is a national-level projected prescription and patient-centric tracking service
 - Receives more than 2.0 Billion prescription claims per year, representing over 160 million unique patients
 - Sample includes 59,000 pharmacies throughout the US
- In total 257 million opioids prescriptions (TRx) delivered each year in US retails pharmacies
 - 91% (233.6 million) are Immediate Release formulation
 - 40% (93.5 million NRx) of Immediate Release are given to new patients
 - 9% (23.1 million) are Extended Release formulations
 - 28% (6.5 million NRx) of Extended Release formulations are for new patients

TRx: Total prescriptions; NRx: New prescriptions Adapted from FDA Office of Surveilance and Epidemiology by L Governale, PharmD, MBA 22JULY2010. "Outpatient prescription opioid utilization in the US: Years 2000-2009."



CONFIDENTIAL - SUBJECT TO PROTECTIVE ORDER



Benefits Of Multimodal Analgesic Therapy

- Reduced doses of each analgesic
- Improved pain relief secondary to synergistic or additive effects of particular agents
- Side effects of individual medications may be reduced
- Outcomes of acute pain are improved

Pain is complex and multifactorial, thus appropriate management requires a "balanced" therapeutic approach

Source: Kehlet H, Dahl JB. Anesth Analg. 1993;77:1048-1056.


CONFIDENTIAL - SUBJECT TO PROTECTIVE ORDER

BARRETT_MDL_00000860

Benefits of Multimodal Analgesia

The effectiveness of multimodal strategies for postoperative pain management has been demonstrated with a variety of medications and therapeutic interventions. The rational use of combinations of analgesic medications, such as nonopioid analgesics, local anesthetic, and opioid analgesia, in addition to other therapeutic interventions can improve pain relief, reduce postoperative adverse effects, and improve functional postoperative recovery for patients.

Kehlet H, Dahl JB. The value of "multimodal" or "balanced analgesia" in postoperative pain treatment. Anesth Analg. 1993;77:1048-1056.



CONFIDENTIAL - SUBJECT TO PROTECTIVE ORDER

BARRETT_MDL_00000862

Clinical Program

- X Well-Controlled Clinical Trials
- Y Open-Label
- Z LT studies
- Demographics
- Overall PT exposure
- Estimated exposures or scripts since launch

CONFIDENTIAL - SUBJECT TO PROTECTIVE ORDER

Clinical Trial Program

PIVOTAL

- CDD-14556 (US) PIVOTAL: R, DB, double-dummy, parallel, moderate to severe cancer pain, n=172, 152 complete; Kadian QD, BID vs MScontin QID
- MOR-9/92 (AU) PIVOTAL: R, DB, double-dummy, 2-period x-over, moderate to severe cancer pain, n=29, 25 complete; Kadian QD, BID vs MScontin QID

Supportive

- MOBES-8/90 (AU): R, DB, double-dummy, 2-period x-over with 12w OL extension, moderate to severe cancer pain, n=27, 24 completed, 20 enter OL, 10 complete OL
- MOR-2/92 (US, incomplete): R, DB, double-dummy, balanced incomplete Block 2 2period x-over, moderate to severe chronic cancer, n=19, 16 completed 6 evaluable
- MOB-1/90 (AU): R, OL, 3-period x-over, moderate to severe cancer pain, n=50, 24 completed
- MOR-5/92: OL, randomized parallel switch, n=49, 37 completed

CONFIDENTIAL - SUBJECT TO PROTECTIVE ORDER

Clinical Trial Program

Long-term safety

- MOS-1/901 (AU): OL, long-term safety/efficacy. 12w OL extension to MOB-1/90: n=19, 9 completed
- MOS-2/91 + 3/91 (AU): OL, long-term safety/efficacy. 9m OL extension to MOB-1/90 and MOBES-8.90: n=29, 8 completed
- MOR-3/92 (AU): OL, long-term safety/efficacy. 12m OL extension to MOS-2/91 and MOS-3/91: n=7, 1 completed

CONFIDENTIAL - SUBJECT TO PROTECTIVE ORDER

Efficacy Parameters

- Primary efficacy parameters amount of rescue medication taken during final 24h of each 7 day period
- Time to first remedication time between morning dose of study med and next dose of active irrespective of whether rescue or regularly-scheduled
- Elapsed time to rescue number of hours from morning dose to first dose of rescue medication
- Total amount of rescue medication taken in 24h of final day
- 0

Ô

 Secondary: VASm 4-point VRS for pain control, 5-point VRS for intensity, 4-point VRS for sleep, 4-point VRS for global assessment, 4-point VRS for investigator PGA

CONFIDENTIAL - SUBJECT TO PROTECTIVE ORDER

Agenda

Clinical Program
MOA/unique formulation
PK/PD
Efficacy/Safety
LT Efficacy/Safety
Dosing flexibility

CONFIDENTIAL - SUBJECT TO PROTECTIVE ORDER

MOA

- Kadian (morphine sulfate) is an opioid agonist
 - Relatively selective for the mu receptor
 - May interact with other opioid receptors at higher doses
- Morphine as a full agonist; analgesia produced by binding with and activating opioid receptors at sites in the peri-aqueductal and peri-ventricular grey matter, ventro-medical medulla and the spinal cord.
- Other widely diverse effects of morphine including dysphoria, euphoria, somnolence, respiratory depression, diminished gastrointestinal motility and altered circulatory dynamics

CONFIDENTIAL - SUBJECT TO PROTECTIVE ORDER

Unique Formulation

[need additional information about the pellets...]

- Polymer-coated sustained-release pellets release morphine at a significantly more slowly than oral morphine solution
 - ~50% of oral morphine reaches systemic circulation in 30 min vs 8 hours with an equivalent dose of Kadian
 - ~20-40% Kadian reaches the systemic circulation
- Kadian can be sprinkled on applesauce for patients who have difficultly swallowing
- Kadian can be administered via a 16 French gastrostomy tube

CONFIDENTIAL - SUBJECT TO PROTECTIVE ORDER

Agenda

Clinical Program
MOA
PK/PD
Efficacy/Safety
LT Efficacy/Safety
Dosing flexibility

CONFIDENTIAL - SUBJECT TO PROTECTIVE ORDER

PK

- Single dose PK of KADIAN are linear over the dosage range of 30-100mg
- At steady state (2 days), KADIAN will have a significantly lower C_{max} and a higher C_{min} than equivalent doses of oral morphine solution and some other extended-release preparations
- KADIAN (QD) had similar C_{max} and higher C_{min} at steady state in clinical usage, when compared to BID extended-release morphine tablets, given at an equivalent total daily dosage
- KADIAN can be administered without regard to meals
- KADIAN *in vivo* testing showed there was not an increase in drug release in the presence of alcohol. However, KADIAN may be expected to have additive effects when used in conjunction with alcohol, other opioids or illicit drugs that cause CNS depression.

CONFIDENTIAL - SUBJECT TO PROTECTIVE ORDER

Agenda

Clinical Program
MOA
PK/PD
Efficacy/Safety
LT Efficacy/Safety
Dosing flexibility

CONFIDENTIAL - SUBJECT TO PROTECTIVE ORDER

BARRETT_MDL_00000872

Efficacy: Pain intensity scores using Visual Analog Scales (VAS)

- Mean VAS pain intensity scores remained consistent during QD dosing...
 - Figure 3 from ISE
 - [need study description for baseline bain]
- Secondary efficacy measures:
 - Sleep
 - Global impression of change

CONFIDENTIAL - SUBJECT TO PROTECTIVE ORDER

Safety

Total exposures
Most common AEs
SAEs
LT safety studies
Post Marketing experience.

CONFIDENTIAL - SUBJECT TO PROTECTIVE ORDER

Dosing Flexibility

- 12 dosing strengths
 - Provides lowest solid oral dosage form of morphine
 - Allows for dose titration up or down
 - BID or QD dosing option
 - No ceiling effect of KADIAN
- Administration options
 - Ability to sprinkle for patients with difficulty swallowing
 - Administration via gastrostomy tube (16 French)
- Other considerations
 - Can be administered without regards to meals
 - KADIAN in vivo testing showed there was not an increase in drug release in the presence of alcohol (dose dumping). However patients should be advised against the consumption of alcohol, illicit drugs or other opioid medications that depress the CNS

CONFIDENTIAL - SUBJECT TO PROTECTIVE ORDER